News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
May 4, 2023
-SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track for 2H 2023- -Strong...
-
Mar 29, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Mar 22, 2023
-Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia- -Cleared IND for...
-
Mar 1, 2023Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
- In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024- -Conference...